Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine Miami, Miami, FL, USA.
Jackson Health System, Miami Transplant Institute, Miami, FL, USA.
Transpl Infect Dis. 2020 Dec;22(6):e13416. doi: 10.1111/tid.13416. Epub 2020 Aug 2.
Coronavirus 2019 (COVID-19) pandemic has resulted in more than 350 000 deaths worldwide. The number of kidney transplants has declined during the pandemic. We describe our deceased donor kidney transplantation (DDKT) experience during the pandemic.
A retrospective study was conducted to evaluate the safety of DDKT during the COVID-19 pandemic. Multiple preventive measures were implemented. Adult patients that underwent DDKT from 3/1/20 to 4/30/20 were included. COVID-19 clinical manifestations from donors and recipients, and post-transplant outcomes (COVID-19 infections, readmissions, allograft rejection, and mortality) were obtained. The kidney transplant (KT) recipients were followed until 5/31/20.
Seventy-six patients received kidneys from 57 donors. Fever, dyspnea, and cough were reported in 1, 2, and 1 donor, respectively. Thirty-eight (66.6%) donors were tested for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) prior to donation (mainly by nasopharyngeal or bronchoalveolar lavage polymerase chain reaction [PCR]) and 36 (47.3%) KT recipients were tested at the time of DDKT by nasopharyngeal PCR; all of these were negative. Our recipients were followed for a median of 63 (range: 33-91) days. A total of 42 (55.3%) recipients were tested post-transplant for SARS-CoV2 by nasopharyngeal PCR including 12 patients that became symptomatic; all tests were negative except for one that was inconclusive, but it was repeated and came back negative. Forty (52.6%) KT recipients were readmitted, and 7 (9.2%) had biopsy-proven rejection during the follow-up. None of the KT recipients transplanted during this period died.
Our cohort demonstrated that DDKT can be safely performed during the COVID-19 pandemic when preventive measures are implemented.
2019 年冠状病毒病(COVID-19)大流行已导致全球超过 35 万人死亡。大流行期间,肾移植数量有所下降。我们描述了大流行期间我们进行的已故供者肾移植(DDKT)经验。
进行了一项回顾性研究,以评估 COVID-19 大流行期间 DDKT 的安全性。实施了多种预防措施。纳入 2020 年 3 月 1 日至 4 月 30 日期间接受 DDKT 的成年患者。获取供者和受者的 COVID-19 临床表现以及移植后结局(COVID-19 感染、再入院、移植物排斥和死亡率)。肾移植(KT)受者随访至 2020 年 5 月 31 日。
76 例患者接受了 57 例供者的肾脏。1 例供者报告发热、呼吸困难和咳嗽,分别为 2 例和 1 例供者。38 例(66.6%)供者在供肾前接受了严重急性呼吸综合征冠状病毒 2(SARS-CoV2)检测(主要通过鼻咽或支气管肺泡灌洗聚合酶链反应[PCR]),36 例(47.3%)KT 受者在 DDKT 时通过鼻咽 PCR 检测;所有这些检测均为阴性。我们的受者随访中位数为 63 天(范围:33-91 天)。共有 42 例(55.3%)受者在移植后接受了鼻咽 PCR 检测 SARS-CoV2,其中 12 例出现症状;除 1 例结果不确定外,所有检测均为阴性,但该检测结果被重复,且为阴性。40 例(52.6%)KT 受者再次入院,7 例(9.2%)在随访期间经活检证实排斥反应。在此期间,没有 KT 受者死亡。
当实施预防措施时,我们的队列表明 COVID-19 大流行期间可以安全进行 DDKT。